CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 86 enrolled
Drug / intervention
AN2728 Topical Ointment, 2% QD +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01602341
NCT01602341Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of AN2728 Ointment Administered Once or Twice a Day in Adolescents With Atopic Dermatitis

Pfizer·interventional·Posted May 21, 2012·Updated Mar 6, 2017

In Brief

A Phase 2 clinical trial evaluating AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, and 2 other interventions for Dermatitis, Atopic. Completed, enrolled 86 participants across 17 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesAustralia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 21, 2012
Enrollment StartAug 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.1 years ago

Interventions

AN2728 Topical Ointment, 2% QDdrug

AN2728 Topical Ointment, 2% QD

AN2728 Topical Ointment, 0.5% QDdrug

AN2728 Topical Ointment, 0.5% QD

AN2728 Topical Ointment, 2% BIDdrug

AN2728 Topical Ointment, 2% BID

AN2728 Topical Ointment, 0.5% BIDdrug

AN2728 Topical Ointment, 0.5% BID